$AMGN Recent News Apple earnings, Fed vie for investor

New Post Public Reply Private Reply Replies (0) Message Board

Jan 26, 2015 at 12:34 PM

$AMGN Recent News

Apple earnings, Fed vie for investor attention this week 5:54 a.m. Today - Wallace Witkowski
FDA panel recommends approval for first generic biotech drug 4:52 p.m. Jan. 7, 2015 - Wallace Witkowski
Novartis wins FDA staff Ok for Neupogen generic 12:46 p.m. Jan. 5, 2015 - Marta Falconi
Amgen and Kite Pharma in cancer immunotherapy pact 10:01 a.m. Jan. 5, 2015 - Tess Stynes
Cal-Maine Foods shares fall on earnings miss 4:41 p.m. Dec. 23, 2014 - Wallace Witkowski
Amgen boosts first-quarter dividend 30% to 79 cents a share 5:46 p.m. Dec. 17, 2014 - Tom Bemis
Amgen ends trials of stomach-cancer therapy 9:58 a.m. Nov. 24, 2014 - Tess Stynes
Amgen's stock drops after trial misses secondary endpoint 9:20 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen's stock drops 2% in premarket trade 9:08 a.m. Nov. 4, 2014 - Tomi Kilgore
Amgen study on cancer treatment misses secondary endpoint 9:07 a.m. Nov. 4, 2014 - Tomi Kilgore
Facebook, Gilead shares fall after hours 5:14 p.m. Oct. 28, 2014 - Wallace Witkowski
Amgen, under investor pressure, outlines strategy 9:05 a.m. Oct. 28, 2014 - MarketWatch.com
Amgen's stock rises after company outlines capital allocation plans 8:08 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen's stock climbs 3.2% in premarket trade after capital allocation plans 7:55 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 revenue $20.8 bln-$21.3 bln vs. FactSet consensus $20.33 bln 7:54 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen sees 2015 adj. EPS $9.05-$9.40 vs. FactSet consensus $9.08 7:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to payout 60% of adj. earnings to shareholders through 2018 7:53 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen plans to raise dividend 30% starting in Q1 2015 7:52 a.m. Oct. 28, 2014 - Tomi Kilgore
Amgen resumes share buybacks, with plans for $2 bln in repurchases through 2015 7:52 a.m. Oct. 28, 2014 - Tomi Kilgore
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 7:35 a.m. Oct. 28, 2014 - Shawn Langlois

FDA accepts cholesterol-lowering med BLA under priority review 7:31 a.m. Today - Seeking Alpha
Will Amgen (AMGN) Keep the Earnings Streak Alive in 4Q? - Analyst Blog 6:25 p.m. Jan. 23, 2015 - Zacks.com
Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog 4:20 p.m. Jan. 23, 2015 - Zacks.com
Will Millennials Drive In 2-0-1-5? 3:33 p.m. Jan. 23, 2015 - Seeking Alpha
What Lessons Has Express Scripts Taught Us? The Future For The Pharmaceutical Industry 7:30 a.m. Jan. 23, 2015 - Seeking Alpha
New Guru Jana Partners' Newest Stock Buys 8:05 p.m. Jan. 22, 2015 - GuruFocus.com
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog 7:00 p.m. Jan. 22, 2015 - Zacks.com
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog 6:35 p.m. Jan. 22, 2015 - Zacks.com
2014 Portfolio Review: Year One Of My DGI Journey, Part I 6:29 p.m. Jan. 22, 2015 - Seeking Alpha
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog 6:00 p.m. Jan. 22, 2015 - Zacks.com
Novartis' Psoriasis Drug Cosentyx Gets FDA Approval - Analyst Blog 5:40 p.m. Jan. 22, 2015 - Zacks.com
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog 4:10 p.m. Jan. 22, 2015 - Zacks.com
Bristol-Myers Makes Leadership Changes, Names New CEO - Analyst Blog 6:13 p.m. Jan. 21, 2015 - Zacks.com
Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog 6:08 p.m. Jan. 21, 2015 - Zacks.com
Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog 5:00 p.m. Jan. 21, 2015 - Zacks.com
Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog 12:50 p.m. Jan. 21, 2015 - Zacks.com
Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog 11:02 a.m. Jan. 21, 2015 - Zacks.com
Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog 6:03 p.m. Jan. 20, 2015 - Zacks.com
Supernus Downgraded as Lead Drugs Face Patent Challenges - Analyst Blog 5:00 p.m. Jan. 20, 2015 - Zacks.com
Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog 3:30 p.m. Jan. 20, 2015 - Zacks.com

Critical Alerts For Infinera Corporation, Pandora, Trulia, ResMed and Amgen Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 4:01 p.m. Jan. 22, 2015 - PR Newswire - PRF
Technology Industry Leaders to Join Gala Global, Inc. Board of Directors 8:01 a.m. Jan. 21, 2015 - GlobeNewswire
Global Cancer Biomarkers Market 2015-2019 1:24 p.m. Jan. 20, 2015 - PR Newswire - PRF
Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer 4:01 p.m. Jan. 15, 2015 - PR Newswire - PRF
Global Ankylosing Spondylitis Market 2015-2019 4:16 p.m. Jan. 14, 2015 - PR Newswire - PRF
NantWorks Announces Launch of an Immuno-Oncology Company, NantCell, and Licensing Agreement with Amgen for an Oncology Antibody 8:01 a.m. Jan. 14, 2015 - BusinessWire - BZX
3D Bioprinting Pioneers RBCC and n3D Biosciences Network With Top Biotechnology Investors This Week at Biotech Showcase 2015 in San Francisco 5:00 a.m. Jan. 13, 2015 - BusinessWire - BZX
Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome 4:01 p.m. Jan. 12, 2015 - PR Newswire - PRF
Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar 9:00 a.m. Jan. 12, 2015 - PR Newswire - PRF
WuXi PharmaTech Acquires NextCODE Health to Create Global Leader in Genomic Medicine 8:00 a.m. Jan. 9, 2015 - PR Newswire - PRF
Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference 4:15 p.m. Jan. 8, 2015 - PR Newswire - PRF
Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies 7:30 a.m. Jan. 8, 2015 - BusinessWire - BZX
Global Psoriasis Therapeutics Market 2015-2019 2:12 p.m. Jan. 7, 2015 - PR Newswire - PRF
Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies 9:00 a.m. Jan. 5, 2015 - PR Newswire - PRF
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma 8:35 a.m. Dec. 31, 2014 - PR Newswire - PRF
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts 9:15 a.m. Dec. 22, 2014 - PR Newswire - PRF
Myriad Genetics Names Bernard Tobin as President of Crescendo Bioscience 7:00 a.m. Dec. 22, 2014 - GlobeNewswire
Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend 5:45 p.m. Dec. 17, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Unlocking Geothermal's Heat Potential in Europe

An Overlooked Powerhouse: Geothermal Heat in Industry These days, it feels like everyone’s got their head in the clouds about renewables—think wind and solar. But under the surface, literally, is geothermal energy, waiting to make a play in Europe’s industrial sector. Project InnerSpace and Future Cleantech Architects are spotlighting a sleeping giant with their...

West Fraser Tackles Grim Quarter: Indefinite Mill Closures

Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....

LUNGevity's Bold $1M Bet on Lung Cancer Research

Investing in the Future of Lung Cancer Research Damn, you don't see this kind of commitment every day! LUNGevity Foundation is dropping over a million bucks on the table to swell the ranks of lung cancer researchers. They're not just tossing dollars at established players; they're betting on fresh minds to shake things up in this critical field. Tackling lung cancer isn't...

SHEIN Expands Compliance Training With UL Solutions

Boosting Seller Compliance Amid Global Standards When you're navigating the cutthroat world of online retail, product compliance isn't just a checkbox—it's your lifeline. SHEIN, a name you're likely familiar with if you're into fast fashion, is doubling down on this by teaming up with UL Solutions. They're holding hands and marching into another training session focused...

Rothera's KPI Swap Approval: A Financial Game Changer

Revolutionizing Risk Management with KPI Swaps Boy, if there's one thing that gets my ticker going, it's the buzz of innovation in financial markets. Rothera just landed a CFTC stamp of approval for something that's about to shake up how institutional traders manage risk: Key Performance Indicator (KPI) swaps. And can you believe it? This isn't just another derivative...

Regal Healthcare: Five Years of Founder-Friendly Valor

Why Founder-Friendly Matters More Than Ever in Healthcare Well folks, in a year when everyone's tossing around terms like 'value-added' and 'strategic support', seeing Regal Healthcare Capital Partners snag slot number five straight on Inc.'s Founder-Friendly Investors list feels like catching a rare breed of fish twice. Seriously, these folks are stamping their forte as...

Jacobi's Harness Brings AI from Concept to Reality

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...